NSE: SUVENPHAR | BSE: 543064

Expensive Performer

Download real time

1058.65 -23.05 (-2.13%)

77.03% Gain from 52W Low

230.3K NSE+BSE Volume

NSE 09 Apr, 2025 3:31 PM (IST)

26,949.5

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Analyst Buy

Goldman Sachs initiates a 'Buy' rating on Suven Pharma; sets a target price of Rs 1,350 See details

Suven Pharmaceuticals Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Suven Pharmaceuticals Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Suven Pharmaceuticals Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Keep track of all breaking news and updates on Suven Pharmaceuticals Ltd. from all sources in a single place.

Load latest

VOTE: Is Suven Pharmaceuticals Ltd. worth buying?

22 Votes:

Buy 63.64%

Sell 13.64%

Hold 22.73%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf